Simon Manyara
Simon Manyara on constant innovation
Search
Brigitte Fuhr
Brigitte Fuhr, our Head of Central Data Science, joined our team to make millions of lives better. Now she’s working on a global program that will transform our ability to develop ground-breaking treatments.
Groundbreaking oncology research zongertinib
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
Alexander Guntur
Touching millions of lives with Alexander Guntur
Bok Oh
Touching millions of lives with Bok Oh
emperor-preserved-heart-failure-full-data
Full results from EMPEROR-Preserved trial demonstrate significant improvement in heart failure outcomes in adults with preserved ejection fraction
Tomato-soup video
A rich tomato soup with crunchy naan croutons and a yogurt swirl topped with fresh coriander.
Cooperation with The Defeat-NCD Partnership
Together with The Defeat-NCD Partnership, Boehringer Ingelheim aims to address key access to healthcare issues related to non-communicable diseases.
Professor Baumgart
Information for people with type 2 diabetes (T2D) on why it is important to consider their heart and suggested measures that can be taken to reduce the risk of heart disease
NEJM-IL-36-Phase-1-GPP-data
Data published in The New England Journal of Medicine show rapid improvement of symptoms in patients with a rare form of pustular psoriasis
Systemic sclerosis physician video
In this video Professor Chris Denton (Consultant Rheumatologist) discusses his experience diagnosing systemic sclerosis, also known as scleroderma
EASi-HF™ Phase III trial in patients with HFpEF
Boehringer Ingelheim's Sandy Sommer on the global urgency for innovative heart failure care and the significance of the clinical trial for patients with HFpEF worldwide.
Central Nervous System Diseases
Find out more about our research and development in central nervous system diseases
Lung Repair & Regeneration Video
Lung repair & regeneration research addresses fundamental changes to lung architecture and how these changes impact lung function.
vet scholars symposium
Veterinary students and researchers from 38 veterinary schools in North America and Europe gathered at the NIH in August to discuss the future of veterinary medicine.
BIVF funding more than doubled to 250 M€
Boehringer Ingelheim increases funding for its corporate venture fund, the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million
TreatmentSequencing
collaboration-LIBD
Boehringer Ingelheim and The Lieber Institute for Brain Development collaborate on centrally acting COMT inhibitors in neuropsychiatric disorders
EMA authorization for Reprocyc ParvoFLEX
Boehringer Ingelheim obtains EMA authorization for Reprocyc® ParvoFLEX, a new porcine parvovirus vaccine
Phase II results cognitive impairment schizophrenia
Presented at ECNP Congress, Phase II trial results demonstrated improvement in cognition with BI 425809 in schizophrenia patients
biolabs-heidelberg
Boehringer Ingelheim supports the launch of BioLabs first European Location in Heidelberg.
DCRI-collaboration-empact-mi
Collaboration with Duke Clinical Research Institute on EMPACT-MI trial, which will assess outcomes in people who have had a myocardial infarction
AMR_Action_Fund
Boehringer Ingelheim joins AMR Action Fund to support antibiotic R&D
CAROLINA-CARMELINA-Asia-analysis
CAROLINA® and CARMELINA® outcome trial subgroup analyses demonstrate cardiovascular and renal safety data in Asian adults with type 2 diabetes
BI_X_Shanghai
Boehringer Ingelheim opens a second branch of its digital lab in Shanghai